Shares of Pacira Pharmaceuticals (PCRX) - Get Report were up 5% in premarket trading on Wednesday after the Parsippany, N.J., company unveiled a collaboration with DePuy Synthes Sales to market and promote the use of Exparel (bupivacaine liposome injectable suspension) for orthopedic procedures in the U.S.

"By benefiting from the scale, existing relationships and commercial capabilities of DePuy Synthes, we aim to broaden and strengthen the adoption and use of Exparel -- especially important given the number of key Exparel data sets in orthopedic procedures that we expect this year," said Pacira chairman and CEO Dave Stack in a news release on Wednesday.

Meanwhile, Clearside Biomedical (CLSD) - Get Report shares were up 2% in premarket trading after ending Tuesday's trading session at $7.93, up nearly 6%. The Alpharetta, Ga.-based company is a developer of therapies for the treatment of back-of-the-eye diseases.

Other stock movers Wednesday morning include Organovo Holdings (ONVO) - Get Report , which was rising by 2% before the market open. San Diego-based Organovo develops three-dimensional human tissues for use in medical research and therapeutic applications.